Reprogramming tumor-associated macrophages with lipid nanosystems reduces PDAC tumor burden and liver metastasis

[Background]: Pancreatic ductal adenocarcinoma (PDAC) requires innovative therapeutic strategies to counteract its progression and metastatic potential. Since the majority of patients are diagnosed with advanced metastatic disease, treatment strategies targeting not only the primary tumor but also m...

Descripción completa

Detalles Bibliográficos
Autores: Palencia-Campos, Adrián, Ruiz-Cañas, Laura, Abal-Sanisidro, Marcelina, López-Gil, Juan Carlos, Batres-Ramos, Sandra, Mendes Saraiva, Sofía, Yagüe, Balbino, Navarro, Diego, Alcalá, Sonia, Rubiolo, Juan A., Bidan, Nadège, Sánchez, Laura, Mura, Simona, Hermann, Patrick C., Fuente, María de la, Sainz, Bruno Jr.
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/383804
Acceso en línea:http://hdl.handle.net/10261/383804
Access Level:acceso abierto
Palabra clave:Pancreatic ductal adenocarcinoma
Tumor-associated macrophages
Tumor microenvironment
Lipid nanoemulsions
Galunisertib
Liver metastasis
Reprogramming
Descripción
Sumario:[Background]: Pancreatic ductal adenocarcinoma (PDAC) requires innovative therapeutic strategies to counteract its progression and metastatic potential. Since the majority of patients are diagnosed with advanced metastatic disease, treatment strategies targeting not only the primary tumor but also metastatic lesions are needed. Tumor-Associated Macrophages (TAMs) have emerged as central players, significantly influencing PDAC progression and metastasis. Our objective was to validate an innovative therapeutic strategy involving the reprogramming of TAMs using lipid nanosystems to prevent the formation of a pro-metastatic microenvironment in the liver.

Similares en LA Referencia